Belgium· BE-AMP-SAM663347-00
Vyloy 100 mg
A zolbetuximab product containing zolbetuximab, registered in Belgium by Astellas Pharma Europe. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Zolbetuximab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX31 (zolbetuximab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Zolbetuximab · ATC L01FX31
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Zolbetuximab
- Manufacturer
- Astellas Pharma Europe
- Country
- Belgium (BE)
- ATC code
- L01FX31
- ATC class
- Zolbetuximab
- Defined daily dose
- 51.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4860649
- be_apb7750177
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Zolbetuximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandVyloy 100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAstellas Pharma AG
- CzechiaVYLOYAstellas Pharma Europe B.V., Leiden
- SpainVYLOY 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- FinlandVyloyAstellas Pharma Europe B.V.
- United KingdomVyloy 100mg powder for concentrate for solution for infusion vialsAstellas Pharma Ltd
- IrelandVyloy 100 mg powder for concentrate for solution for infusion.Astellas Pharma Europe B.V.
- IcelandVyloyAstellas Pharma Europe B.V.
- NorwayVyloyAstellas Pharma Europe B.V
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyloy
- Liechtenstein · Vyloy
- Norway · Vyloy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c65eda69-94ab-407d-ab35-4b4417e7e7c2 GET /v1/drugs/c65eda69-94ab-407d-ab35-4b4417e7e7c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Vyloy 100 mg",
"name_fr": "Vyloy 100 mg",
"name_nl": "Vyloy 100 mg",
"amp_code": "SAM663347-00",
"strengths": [
"100.0000",
"100.0000",
"0.2100"
],
"pack_count": 2,
"substances": [
"Zolbetuximab",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Zolbetuximab",
"authorisation_numbers": [
"EU/1/24/1856/002",
"EU/1/24/1856/001"
]
}See everything about zolbetuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.